Mar. Drugs 2013, 11(10), 4035-4049; doi:10.3390/md11104035
Article

Identification of Two Novel Anti-Fibrotic Benzopyran Compounds Produced by Engineered Strains Derived from Streptomyces xiamenensis M1-94P that Originated from Deep-Sea Sediments

1 State Key Laboratory of Microbial Metabolism and School of Life Science & Biotechnology, State Key Laboratory of Ocean Engineering, Shanghai Jiao Tong University, Shanghai 200240, China 2 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, China 3 Ministry of Education Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China 4 Key Laboratory of Marine Biogenetic Resources, the Third Institute of Oceanography SOA, Xiamen 361005, Fujian, China 5 Instrumental Analysis Center, Shanghai Jiao Tong University, Shanghai 200240, China
* Author to whom correspondence should be addressed.
Received: 17 August 2013; in revised form: 16 September 2013 / Accepted: 26 September 2013 / Published: 22 October 2013
(This article belongs to the Special Issue Advances and New Perspectives in Marine Biotechnology)
PDF Full-text Download PDF Full-Text [691 KB, uploaded 22 October 2013 12:10 CEST]
Abstract: The benzopyran compound obtained by cultivating a mangrove-derived strain, Streptomyces xiamenensis strain 318, shows multiple biological effects, including anti-fibrotic and anti-hypertrophic scar properties. To increase the diversity in the structures of the available benzopyrans, by means of biosynthesis, the strain was screened for spontaneous rifampicin resistance (Rif), and a mutated rpsL gene to confer streptomycin resistance (Str), was introduced into the S. xiamenensis strain M1-94P that originated from deep-sea sediments. Two new benzopyran derivatives, named xiamenmycin C (1) and D (2), were isolated from the crude extracts of a selected Str-Rif double mutant (M6) of M1-94P. The structures of 1 and 2 were identified by analyzing extensive spectroscopic data. Compounds 1 and 2 both inhibit the proliferation of human lung fibroblasts (WI26), and 1 exhibits better anti-fibrotic activity than xiamenmycin. Our study presents the novel bioactive compounds isolated from S. xiamenensis mutant strain M6 constructed by ribosome engineering, which could be a useful approach in the discovery of new anti-fibrotic compounds.
Keywords: Streptomyces xiamenensis; ribosome engineering; benzopyran; anti-fibrosis

Supplementary Files

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

You, Z.-Y.; Wang, Y.-H.; Zhang, Z.-G.; Xu, M.-J.; Xie, S.-J.; Han, T.-S.; Feng, L.; Li, X.-G.; Xu, J. Identification of Two Novel Anti-Fibrotic Benzopyran Compounds Produced by Engineered Strains Derived from Streptomyces xiamenensis M1-94P that Originated from Deep-Sea Sediments. Mar. Drugs 2013, 11, 4035-4049.

AMA Style

You Z-Y, Wang Y-H, Zhang Z-G, Xu M-J, Xie S-J, Han T-S, Feng L, Li X-G, Xu J. Identification of Two Novel Anti-Fibrotic Benzopyran Compounds Produced by Engineered Strains Derived from Streptomyces xiamenensis M1-94P that Originated from Deep-Sea Sediments. Marine Drugs. 2013; 11(10):4035-4049.

Chicago/Turabian Style

You, Zhong-Yuan; Wang, Ya-Hui; Zhang, Zhi-Gang; Xu, Min-Juan; Xie, Shu-Jie; Han, Tie-Sheng; Feng, Lei; Li, Xue-Gong; Xu, Jun. 2013. "Identification of Two Novel Anti-Fibrotic Benzopyran Compounds Produced by Engineered Strains Derived from Streptomyces xiamenensis M1-94P that Originated from Deep-Sea Sediments." Mar. Drugs 11, no. 10: 4035-4049.

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert